Drug intelligence / Profile preview

RC68-MC-VC-PAB-MMAE

Development stage: Preclinical
Lead developer: RemeGen
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RC68-MC-VC-PAB-MMAE is a **novel antibody-drug conjugate (ADC)** composed of a humanized anti-EGFR monoclonal antibody (RC68) conjugated to monomethyl auristatin E (MMAE), a potent tubulin inhibitor, via a maleimidocaproyl-valine-citrulline-p-aminobenzyl (MC-VC-PAB) linker. The drug specifically targets **epidermal growth factor receptor (EGFR)** expressed on tumor cells. After binding to EGFR, the ADC is internalized and releases MMAE, which disrupts microtubule dynamics leading to cell death. It has demonstrated significant **anti-tumor activity** against EGFR-positive non-small cell lung cancer (NSCLC) and pancreatic cancer in preclinical models, showing greater efficacy than docetaxel and gemcitabine in respective xenograft models[1][5][7]. RC68-MC-VC-PAB-MMAE is distinct from other RC68 conjugates due to its MC-VC-PAB linker, which influences its pharmacodynamic and stability profile.

Brand names: RC68-MC-VC-PAB-MMAERC-68-MC-VC-PAB-MMAERC 68-MC-VC-PAB-MMAE
Other names: RC68-MC-VC-PAB-MMAERC-68-MC-VC-PAB-MMAERC 68-MC-VC-PAB-MMAE

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on RC68-MC-VC-PAB-MMAE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RC68-MC-VC-PAB-MMAE.

Explore the full profile